Feasibility and potential effects of mental imagery training on subjective cognitive function and brain connectivity in people with Parkinson's disease: A randomized pilot trial.

Neuropsychol RehabilJan 3, 2026 (epub)
Clinical ResearchNeurology

Jared Cherry, Alyssa M Nelson, Lauren A Robinson et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized pilot trial assessed the feasibility of remotely delivered, personalized mental imagery training for goal-directed daily activities in nondemented people with Parkinson’s disease, compared with psychoeducation on cognitive health. Of 51 people screened, 30 were randomized. Retention and compliance with study procedures were 100% during the six-week training period. The study also explored self-reported cognitive function and functional MRI measures at baseline, six weeks, and 18 weeks. Group differences in cognitive-function scores and brain connectivity were observed, but the authors state that these changes require testing in a fully powered trial.

Key findings

  • Retention and compliance with study procedures were 100% during the six-week training period.
  • Neuro-QoL Cognitive Function T-scores differed between groups at six and 18 weeks, driven by a reduction in control-group scores.
  • At six weeks, the mental imagery group showed stronger frontoparietal connectivity than the control group.
  • At 18 weeks, the mental imagery group showed weaker visuospatial-motor connectivity during imagery tasks than the control group.

Why it matters

Cognitive impairment in Parkinson’s disease is described as debilitating, with no effective treatment. This pilot suggests that remote mental imagery training and the proposed cognitive and imaging measures can be implemented in a study setting. The exploratory group differences provide outcomes to investigate further, but do not establish that the intervention improves cognition or brain function.

What to keep in mind

This was a pilot trial with 30 randomized participants; the cognitive and connectivity findings were exploratory and require confirmation in a fully powered trial.

Source

Published in Neuropsychol Rehabil. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.